Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia

Leukemia

Volumn 28, Issue 6, 2014, Pages 1196-1206

  Lonetti, A ^a   Antunes, I L ^b   Chiarini, F ^c,d   Orsini, E ^a   Buontempo, F ^a   Ricci, F ^e   Tazzari, P L ^e   Pagliaro, P ^e   Melchionda, F ^e   Pession, A ^e   Bertaina, A ^f   Locatelli, F ^f   Mccubrey, J A ^g   Barata, J T ^b   Martelli, A M ^a,c,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c CNR   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g EAST CAROLINA UNIVERSITY   (United States)

Author keywords

apoptosis; cell cycle; chemotherapy; PI3K; T cell acute lymphoblastic leukemia; targeted therapy

Indexed keywords

ABC TRANSPORTER; BUPARLISIB; CASPASE 2; CASPASE 3; CASPASE 9; CD3 ANTIGEN; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DEPHOSPHORYLATION; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MAXIMUM PLASMA CONCENTRATION; MESENCHYMAL STROMA CELL; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; T CELL LEUKEMIA; T LYMPHOBLAST; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

AMINOPYRIDINES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902080598     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.369     Document Type: Article

References (60)

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011; 117: 5019-5032.
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043. (Pubitemid 351389536)
3. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 2013; 27: 1000-1008.
4. Iacobucci I, Papayannidis C, Lonetti A, Ferrari A, Baccarani M, Martinelli G. Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: Recent developments. Curr Hematol Malig Rep 2012; 7: 133-143.
5. Bains T, Heinrich MC, Loriaux MM, Beadling C, Nelson D, Warrick A et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2144-2146.
6. Jenkinson S, Koo K, Mansour MR, Goulden N, Vora A, Mitchell C et al. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 2013; 27: 41-47.
7. Blackburn JS, Liu S, Raiser DM, Martinez SA, Feng H, Meeker ND et al. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 2012; 26: 2069-2078.
8. Lhermitte L, Ben Abdelali R, Villarese P, Bedjaoui N, Guillemot V, Trinquand A et al. Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL. Leukemia 2013; 27: 305-314.
9. Cialfi S, Palermo R, Manca S, Checquolo S, Bellavia D, Pelullo M et al. Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression. Leukemia 2013; 27: 485-488.
10. Malyukova A, Brown S, Papa R, OBrien R, Giles J, Trahair TN et al. FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. Leukemia 2013; 27: 1053-1062.
11. Correia NC, Durinck K, Leite AP, Ongenaert M, Rondou P, Speleman F et al. Novel TAL1 targets beyond protein-coding genes: Identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. Leukemia 2013; 27: 1603-1606.
12. Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang H et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-Alpha and cAMP/PKA pathways. Leukemia 2012; 26: 769-777.
13. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: From biological players to clinical contributors. Leukemia 2012; 26: 1-12.
14. Patel B, Kang Y, Cui K, Litt M, Riberio MSJ, Deng C et al. Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia. Leukemia 2014; 28: 349-361.
15. Lo Nigro L, Mirabile E, Tumino M, Caserta C, Cazzaniga G, Rizzari C et al. Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. Leukemia 2013; 27: 2419-2421.
16. Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, Van Der Velden VH et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia 2013; 27: 1497-1503.
17. Juntilla MM, Koretzky GA. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett 2008; 116: 104-110.
18. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707. (Pubitemid 351565618)
19. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
20. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762-3774.
21. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203-1210. (Pubitemid 47530629)
22. Silva A, Girio A, Cebola I, Santos CI, Antunes F, Barata JT. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25: 960-967.
23. Zenatti PP, Ribeiro D, Li WQ, Zuurbier L, Silva MC, Paganin M et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011; 43: 932-U931.
24. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2336-2342.
25. Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 2013; 27: 650-660.
26. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012; 11: 317-328.
27. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J MolMed 2012; 90: 695-706.
28. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int J Cancer 2013; 133: 247-252.
29. Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K et al. Inhibition of pan-class I PI3 kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B cell lymphoma. Leuk Lymphoma 2013; e-pub ahead of print 31 May 2013; doi:10.3109/10428194.2013. 806800.
30. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282-290.
31. Matarrese P, Testa U, Cauda R, Vella S, Gambardella L, Malorni W. Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondriamediated apoptosis. Biochem J 2001; 355: 587-595. (Pubitemid 32434074)
32. Silva A, Laranjeira ABA, Martins LR, Cardoso BA, Demengeot J, Yunes JA et al. IL-7 contributes to the progression of human t-cell acute lymphoblastic leukemias. Cancer Res 2011; 71: 4780-4789.
33. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.
34. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
35. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781-791.
36. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22: 147-160.
37. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: Therapeutic implications. Leukemia 2012; 26: 91-100.
38. Telford WG, Bradford J, Godfrey W, Robey RW, Bates SE. Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells 2007; 25: 1029-1036. (Pubitemid 46572601)
39. Martins LR, Lucio P, Melao A, Antunes I, Cardoso BA, Stansfield R et al. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia 2014; 28: 179-182.
40. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
41. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-Tumor activity in acute myeloid leukemia. Leukemia 2012; 26: 1195-1202.
42. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resist Updat 2009; 12: 103-113.
43. Li J, Law HK, Lau YL, Chan GC. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 2004; 127: 326-334. (Pubitemid 39468948)
44. Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M, Momose H, Masumi A et al. Identification of cancer stem cells in a Tax-Transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood 2009; 114: 2709-2720.
45. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006; 312: 3701-3710.
46. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034. (Pubitemid 32937383)
47. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-T hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532.
48. Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther 2012; 11: 1747-1757.
49. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006; 98: 545-556. (Pubitemid 43898818)
50. Casale F, D'Angelo V, Addeo R, Caraglia M, Crisci S, Rondelli R et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 2004; 12: 1201-1207.
51. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N et al. Antitumor activity of NVP-BKM120-A selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 2012; 18: 184-195.
52. Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR et al. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-Type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 2012; 69: 1601-1615.
53. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2: 1048-1063.
54. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triplenegative breast cancer to PARP inhibition. Cancer Discov 2012; 2: 1036-1047.
55. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: Current concepts and therapeutic opportunities. Blood 2009; 114: 1150-1157.
56. Kantarjian H, Thomas D, OBrien S, Cortes J, Giles F, Jeha S et al. Long-Term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801. (Pubitemid 39603187)
57. Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell 2012; 21: 459-472.
58. Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009; 69: 3520-3528.
59. Stengel C, Jenner E, Meja K, Mayekar S, Khwaja A. Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity. Br J Haematol 2013; 162: 285-289.
60. Fruman DA, Rommel C. PI3Kd inhibitors in cancer: Rationale and serendipity merge in the clinic. Cancer Discov 2011; 1: 562-572. a Tecnologia